Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma

[1]  Irinotecan , 2018, Reactions Weekly.

[2]  Zhi-sheng Xu,et al.  Effects of cytochrome P450 family 3 subfamily A member 5 gene polymorphisms on daunorubicin metabolism and adverse reactions in patients with acute leukemia , 2017, Molecular medicine reports.

[3]  P. Nathan,et al.  Imaging of late complications of cancer therapy in children , 2017, Pediatric Radiology.

[4]  N. Chaiyakunapruk,et al.  Candidate Gene Association Studies of Anthracycline-induced Cardiotoxicity: A Systematic Review and Meta-analysis , 2017, Scientific Reports.

[5]  M. Coenen,et al.  The role of pharmacogenetics in the treatment of osteosarcoma. , 2016, Drug discovery today.

[6]  M. Hayden,et al.  Recommendations for genetic testing to reduce the incidence of anthracycline‐induced cardiotoxicity , 2016, British journal of clinical pharmacology.

[7]  A. Billett.  How Should Pediatric Cancer Be Included in the Cancer Moonshot , 2016 .

[8]  A. Arany,et al.  Pharmacogenetic analysis of high-dose methotrexate treatment in children with osteosarcoma , 2016, Oncotarget.

[9]  A. Roli,et al.  Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma , 2016, Oncotarget.

[10]  A. Gézsi,et al.  Pharmacogenetics of anthracyclines. , 2016, Pharmacogenomics.

[11]  A. Garnier,et al.  Sex differences in anthracycline cardiotoxicity , 2016 .

[12]  Nicholas J. Seewald,et al.  Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines. , 2016, Pharmacogenomics.

[13]  E. Soliman,et al.  Cardiac Outcomes in Adult Survivors of Childhood Cancer Exposed to Cardiotoxic Therapy , 2016, Annals of Internal Medicine.

[14]  Smita H. Karande,et al.  A Coding Variant in RARG Confers Susceptibility to Anthracycline-Induced Cardiotoxicity in Childhood Cancer , 2015, Nature Genetics.

[15]  P. Neven,et al.  Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients , 2015, Breast Cancer Research and Treatment.

[16]  M. Ziepert,et al.  Association of NADPH oxidase polymorphisms with anthracycline-induced cardiotoxicity in the RICOVER-60 trial of patients with aggressive CD20(+) B-cell lymphoma. , 2015, Pharmacogenomics.

[17]  U. Vogel,et al.  High ABCC2 and Low ABCG2 Gene Expression Are Early Events in the Colorectal Adenoma-Carcinoma Sequence , 2015, PloS one.

[18]  T. Nánási,et al.  Polymorphism in the Serotonin Receptor 2a (HTR2A) Gene as Possible Predisposal Factor for Aggressive Traits , 2015, PloS one.

[19]  M. Garami,et al.  [Importance of the National Childhood Cancer Registry in the field of paediatric oncology care in Hungary]. , 2014, Orvosi hetilap.

[20]  Kevin C Oeffinger,et al.  Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  H. Hakonarson,et al.  Hyaluronan synthase 3 variant and anthracycline-related cardiomyopathy: a report from the children's oncology group. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  V. García-Martínez,et al.  The decrease of NAD(P)H:quinone oxidoreductase 1 activity and increase of ROS production by NADPH oxidases are early biomarkers in doxorubicin cardiotoxicity , 2014, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[23]  S. Neuhausen,et al.  Genetic susceptibility to anthracycline‐related congestive heart failure in survivors of haematopoietic cell transplantation , 2013, British journal of haematology.

[24]  R. Riccardi,et al.  Myocardial performance index and biochemical markers for early detection of doxorubicin-induced cardiotoxicity in children with acute lymphoblastic leukaemia , 2013, International Journal of Clinical Oncology.

[25]  A. Falus,et al.  Roles of Genetic Polymorphisms in the Folate Pathway in Childhood Acute Lymphoblastic Leukemia Evaluated by Bayesian Relevance and Effect Size Analysis , 2013, PloS one.

[26]  M. Hayden,et al.  Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline‐induced cardiotoxicity in children , 2013, Pediatric blood & cancer.

[27]  E. Lopez-Lopez,et al.  Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia , 2013, Pharmacogenetics and genomics.

[28]  H. Miao,et al.  Gene polymorphisms of ABC transporters are associated with clinical outcomes in children with acute lymphoblastic leukemia , 2012, Archives of medical science : AMS.

[29]  P. Regitnig,et al.  Analysis of functional germline polymorphisms for prediction of response to anthracycline-based neoadjuvant chemotherapy in breast cancer , 2012, Molecular Genetics and Genomics.

[30]  Zhaoqian Liu,et al.  ABCC2 Polymorphisms and Haplotype are Associated with Drug Resistance in Chinese Epileptic Patients , 2012, CNS neuroscience & therapeutics.

[31]  A. Le Cesne,et al.  A role for maintenance therapy in managing sarcoma. , 2012, Cancer treatment reviews.

[32]  H. Krum,et al.  Antagonists of organic anion transporters 1 and 3 ameliorate adverse cardiac remodelling induced by uremic toxin indoxyl sulfate. , 2012, International journal of cardiology.

[33]  A. Sasse,et al.  Is there a role for consolidative radiotherapy in the treatment of aggressive and localized Non-Hodgkin Lymphoma? A systematic review with meta-analysis , 2012, BMC Cancer.

[34]  S. Glück,et al.  Systemic therapy options in BRCA mutation-associated breast cancer , 2012, Breast Cancer Research and Treatment.

[35]  L. F. Glass,et al.  Primary cutaneous B-cell lymphomas: recent advances in diagnosis and management. , 2012, Cancer control : journal of the Moffitt Cancer Center.

[36]  M. Niemi,et al.  PPARA: A Novel Genetic Determinant of CYP3A4 In Vitro and In Vivo , 2012, Clinical pharmacology and therapeutics.

[37]  T. Mekhail,et al.  Thymic Neoplasms: a Clinical Update , 2012, Current Oncology Reports.

[38]  M. Hayden,et al.  Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  D. Ross,et al.  NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones. , 2012, Biochemical pharmacology.

[40]  L. Robison.  Late effects of acute lymphoblastic leukemia therapy in patients diagnosed at 0-20 years of age. , 2011, Hematology. American Society of Hematology. Education Program.

[41]  S. Bhatia.  Role of Genetic Susceptibility in Development of Treatment-Related Adverse Outcomes in Cancer Survivors , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[42]  Ursula Amstutz,et al.  Pharmacogenomics of Cardiovascular Drugs and Adverse Effects in Pediatrics , 2011, Journal of cardiovascular pharmacology.

[43]  E. Gamazon,et al.  Genome-wide Meta-analysis Identifies Variants Associated with Platinating Agent Susceptibility Across Populations , 2011, The Pharmacogenomics Journal.

[44]  Nima Ghasemzadeh,et al.  A Brief Journey into the History of the Arterial Pulse , 2011, Cardiology research and practice.

[45]  Tina Hernandez-Boussard,et al.  Doxorubicin pathways: pharmacodynamics and adverse effects , 2011, Pharmacogenetics and genomics.

[46]  Wendy McClellan,et al.  Late Effects of Childhood Leukemia Therapy , 2011, Current hematologic malignancy reports.

[47]  B. Suys,et al.  Late cardiotoxicity after low dose of anthracycline therapy for acute lymphoblastic leukemia in childhood , 2011, Journal of Cancer Survivorship.

[48]  M. Krajinovic,et al.  Polymorphism in multidrug resistance-associated protein gene 3 is associated with outcomes in childhood acute lymphoblastic leukemia , 2011, The Pharmacogenomics Journal.

[49]  J. Fulbright.  Review of Cardiotoxicity in Pediatric Cancer Patients: During and after Therapy , 2011, Cardiology research and practice.

[50]  Jenny Marder.  Cancer research. Childhood's cures haunted by adulthood's 'late effects'. , 2010, Science.

[51]  P. Kaatsch.  Epidemiology of childhood cancer. , 2010, Cancer treatment reviews.

[52]  C. Lampic,et al.  Long‐term survivors of childhood cancer report quality of life and health status in parity with a comparison group , 2010, Pediatric blood & cancer.

[53]  S. Lipshultz,et al.  Cardiotoxicity after childhood cancer: beginning with the end in mind. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  W. Figg,et al.  Pharmacogenetics of Membrane Transporters: An Update on Current Approaches , 2010, Molecular biotechnology.

[55]  H. Sather,et al.  Long Term Results of the Children’s Cancer Group Studies for Childhood Acute Lymphoblastic Leukemia 1983–2002: a Children’s Oncology Group Report , 2009, Leukemia.

[56]  D. Mulrooney,et al.  Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort , 2009, BMJ : British Medical Journal.

[57]  Hong-yan Cheng,et al.  MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer , 2009, Cancer Chemotherapy and Pharmacology.

[58]  E. Yeh,et al.  Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. , 2009, Journal of the American College of Cardiology.

[59]  G. Armstrong,et al.  Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  T. Grigliatti,et al.  Two Nonsynonymous Single Nucleotide Polymorphisms of Human Carbonyl Reductase 1 Demonstrate Reduced in Vitro Metabolism of Daunorubicin and Doxorubicin , 2009, Drug Metabolism and Disposition.

[61]  R. Pieters,et al.  Beneficial and harmful effects of anthracyclines in the treatment of childhood acute lymphoblastic leukaemia: a systematic review and meta-analysis. , 2009, British journal of haematology.

[62]  B. Giardina,et al.  New developments in anthracycline-induced cardiotoxicity. , 2009, Current medicinal chemistry.

[63]  D. Rossi,et al.  Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21 , 2009, Leukemia.

[64]  I. Mlinarič-Raščan,et al.  Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood , 2009, Leukemia & lymphoma.

[65]  I. Janszky,et al.  Synergistic interaction of ABCB1 and ABCG2 polymorphisms predicts the prevalence of toxic encephalopathy during anticancer chemotherapy , 2008, The Pharmacogenomics Journal.

[66]  P. Ang,et al.  CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients , 2008, Cancer science.

[67]  A. Neugut,et al.  Anthracycline cardiotoxicity: one size does not fit all! , 2008, Journal of the National Cancer Institute.

[68]  P. Viale,et al.  Cardiovascular toxicity associated with cancer treatment. , 2008, Clinical journal of oncology nursing.

[69]  M. Relling,et al.  Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline‐related congestive heart failure after childhood cancer , 2008, Cancer.

[70]  L. Robison,et al.  Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. , 2008, Blood.

[71]  T. Pfeifer,et al.  Two Allelic Variants of Aldo-Keto Reductase 1A1 Exhibit Reduced in Vitro Metabolism of Daunorubicin , 2008, Drug Metabolism and Disposition.

[72]  P. Ang,et al.  Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients , 2008, Cancer science.

[73]  S. Lipshultz,et al.  Anthracycline associated cardiotoxicity in survivors of childhood cancer , 2007, Heart.

[74]  G. Minotti,et al.  An introduction to the metabolic determinants of anthracycline cardiotoxicity , 2007, Cardiovascular Toxicology.

[75]  Y. Fujio,et al.  Degradation of NFAT5, a Transcriptional Regulator of Osmotic Stress-related Genes, Is a Critical Event for Doxorubicin-induced Cytotoxicity in Cardiac Myocytes* , 2007, Journal of Biological Chemistry.

[76]  P. Neuvonen,et al.  Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics , 2006, Pharmacogenetics and genomics.

[77]  K. Ushinohama,et al.  Effect of methotrexate treatment on expression levels of multidrug resistance protein 2, breast cancer resistance protein and organic anion transporters Oat1, Oat2 and Oat3 in rats , 2006, Cancer science.

[78]  C. Pui,et al.  Treatment of acute lymphoblastic leukemia. , 2006, The New England journal of medicine.

[79]  M. Pfreundschuh,et al.  NAD(P)H Oxidase and Multidrug Resistance Protein Genetic Polymorphisms Are Associated With Doxorubicin-Induced Cardiotoxicity , 2005, Circulation.

[80]  Michael S Ewer,et al.  Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. , 2004, Circulation.

[81]  G. Salles,et al.  Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  John D. Storey.  A direct approach to false discovery rates , 2002 .

[83]  P. Voûte,et al.  Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[84]  E J Orav,et al.  Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. , 1995, The New England journal of medicine.

[85]  A. Giordano,et al.  Cardiovascular Complications in Cancer Therapy , 2019, Current Clinical Pathology.

[86]  P. Nathan,et al.  Imaging of acute and subacute toxicities of cancer therapy in children , 2015, Pediatric Radiology.

[87]  W. Carroll,et al.  Clinical and laboratory biology of childhood acute lymphoblastic leukemia. , 2012, The Journal of pediatrics.

[88]  Lucila I. Castro-Pastrana,et al.  Pharmacogenomics of serious adverse drug reactions in pediatric oncology. , 2011, Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharamcologie clinique.

[89]  W. N. Chen,et al.  Pharmacogenetics of target genes across doxorubicin disposition pathway: a review. , 2010, Current drug metabolism.

[90]  S. Marsh,et al.  Irinotecan pharmacogenomics. , 2010, Pharmacogenomics.

[91]  R. Calabro',et al.  Anthracycline-Induced Cardiotoxicity in Children with Cancer , 2005, Paediatric drugs.

[92]  D. Labuda,et al.  Childhood Acute Lymphoblastic Leukemia: Genetic Determinants of Susceptibility and Disease Outcome , 2001, Reviews on environmental health.

[93]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .